[1] NATALE P, PALMER S C, RUOSPO M, et al. Anticoagulation for people receiving long-term haemodialysis[J]. Cochrane Database Syst Rev, 2024, 1(1): CD011858. doi:  10.1002/14651858.cd011858
[2] AREPALLY G M. Heparin-induced thrombocytopenia[J]. Blood, 2017, 129(21): 2864-2872. doi:  10.1182/blood-2016-11-709873
[3] LINKINS L A, DANS A L, MOORES L K, et al. Treatment and prevention of heparin-induced thrombocytopenia antithrombotic therapy and prevention of thrombosis, 9th Ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2): e495S-e530S.
[4] 黄馥菡, 施向东. 100例尿毒症血液透析患者肝素诱导的血小板减少症发病率及临床特点[J]. 浙江实用医学, 2011, 16(4): 259-261. doi:  10.3969/j.issn.1007-3299.2011.04.010
[5] 中国医师协会心血管内科医师分会血栓防治专业委员会, 《中华医学杂志》编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志, 2018, 98(6): 408-417.
[6] TULEJA A, SALVADOR D Jr, MUKA T, et al. Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia[J]. Blood Adv, 2022, 6(10): 3114-3125. doi:  10.1182/bloodadvances.2022007017
[7] LAI B B, HUANG W X, YU H, et al. Citrate as a safe and effective alternative to heparin for catheter locking: a systematic review and meta-analysis of randomized controlled trials[J]. Front Med, 2025, 12: 1530619. doi:  10.3389/fmed.2025.1530619
[8] LEE G M, AREPALLY G M. Diagnosis and management of heparin-induced thrombocytopenia[J]. Hematol Oncol Clin North Am, 2013, 27(3): 541-563.
[9] LARSEN E L, NILIUS H, STUDT J D, et al. Accuracy of diagnosing heparin-induced thrombocytopenia[J]. JAMA Netw Open, 2024, 7(3): e243786. doi:  10.1001/jamanetworkopen.2024.3786
[10] 赵明, 李向东, 李毅, 等. 维持性血液透析患者肝素诱导的血小板减少症的临床观察[J]. 临床肾脏病杂志, 2014, 14(12): 730-733.
[11] Genovesi S, Camm A J, Covic A, 等. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation[J]. Nephrology Dialysis Transplantation, 2024, 39(8): 1248-1257.
[12] 葛海沂, 丁楠. 1例Ⅱ型血小板减少症的药学监护并文献复习[J]. 药学实践杂志, 2019, 37(3): 279-282. doi:  10.3969/j.issn.1006-0111.2019.03.018
[13] 管文婕, 陈慧慧, 汪涛, 等. 冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护[J]. 药学实践杂志, 2019, 37(4): 370-374. doi:  10.3969/j.issn.1006-0111.2019.04.017
[14] WALENGA J M. An overview of the direct thrombin inhibitor argatroban[J]. Pathophysiol Haemos Thromb, 2003, 32(Suppl.3): 9-14. doi:  10.1159/000069103
[15] 魏盼, 张世强, 权冬梅, 等. 定期阿加曲班抗凝对血液透析患者长期留置导管预防血栓形成的疗效观察[J]. 透析与人工器官, 2020, 31(4): 14-16.
[16] 黄丹, 章志俊. 利伐沙班在非瓣膜性房颤患者中的应用效果[J]. 中国医学创新, 2026, 23(3): 78-81.
[17] LI W H, ZHOU Y X, CHEN S Q, et al. Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis[J]. Front Cardiovasc Med, 2022, 9: 1005742. doi:  10.3389/fcvm.2022.1005742
[18] 李莹, 钱皎, 朱全刚. 临床药师参与心脏瓣膜置换术后患者的药学服务实践与体会[J]. 药学实践与服务, 2023, 41(4): 255-258.